Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity

Reuters

2025/11/05

<a href="https://laohu8.com/S/BMEA">Biomea Fusion</a> Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity

Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek® 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568770-en) on November 05, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581721550"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581721550\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581721550?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581721550","market":"us","top_or_hot":-1,"title":"Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BMEA\">Biomea Fusion</a> Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek® 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568770-en) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-05 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BMEA\">Biomea Fusion</a> Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek® 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568770-en) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMEA","symbol_name":"Biomea Fusion, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL8hj9Jr:1","article_id":"2581721550","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581721550","pubTimestamp":1762344034,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BMEA":"Biomea Fusion, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4539":"次新股","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Biomea Fusion启动口服GLP-1激动剂BMF-650治疗肥胖症I期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMEA":0.9,"NDAQ":0.9},"content_text":"Biomea Fusion Launches Phase I Trial of Oral GLP-1 Agonist BMF-650 for Obesity\n    \n\n        Biomea Fusion Inc. has announced the presentation of preclinical data for its investigational oral small molecule GLP-1 receptor agonist, BMF-650, and combination data for its covalent menin inhibitor candidate, icovamenib, with semaglutide at ObesityWeek® 2025. The preclinical studies demonstrated that BMF-650 produced potent weight loss and strong glycemic control in obese cynomolgus monkeys, with improvements in insulin sensitivity and preservation of lean mass. Additionally, in a rodent model of type 2 diabetes, the combination of icovamenib and low dose semaglutide showed enhanced glycemic control and body weight reduction compared to semaglutide alone. A Phase I study of BMF-650 in healthy obese patients is currently enrolling, with data expected in the first half of 2026. Biomea Fusion plans to begin clinical evaluation of icovamenib in patients with type 2 diabetes on GLP-1 based treatment in the fourth quarter of 2025, with first patient dosing expected in the first quarter of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568770-en) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}